US FDA grants fast track designation to DualityBio's next-generation HER3 ADC DB-1310 to treat nonsquamous non-small ...
DualityBio, a clinical-stage biotech company dedicated to the discovery and development of next-generation ADC, announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting antibody …